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Available online 16 July 2014Abstract A growing body of evidence has shown that the heart is not terminally differentiated but continues to renew its
cardiomyocytes even after the neonatal period. This new view of the heart increases hope for changing the strategy for
treating cardiac injuries toward regenerative approaches. However, the magnitude and clinical significance of this process in
homeostasis and disease and the underlying cellular and molecular mechanisms have been heavily debated. Numerous
candidates for so-called cardiac stem cells (CSCs) have been proposed, but the different characteristics of these candidates
make it difficult to identify the inherent source of regeneration. In this review, we revisit the field of cardiac stem cells and
endogenous regeneration to elaborate how these fields may contribute to future regenerative strategies.
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Most studies agree that the adult heart continues to renew
cardiomyocytes even after the neonatal period.
Cardiomyocytes can be generated by self-duplication andn access article under the CC BY-NC-ND license
Figure 1 Modes of cardiomyocyte renewal. Adult-born cardio-
myocyte can be derived from a CSC pool or by self-replication,
possibly involving dedifferentiation. Both modes have been
documented and might exist in parallel. A fraction of
cardiomyocytes entering the cell cycle exit prematurely and
becomes polyploid and/or multinucleated.
524 O. Bergmann, S. Jovingeby cardiac stem cells (CSCs) (Fig. 1). Both modes of
cardiomyocyte renewal have been proposed at different
ages and after cardiac injury. However, the magnitude of
myocyte turnover in homeostasis and disease has beenTable 1 Cardiomyocyte renewal in adult hearts. Cardiomyocyte: CM
H3: p-H3; *converted to percentage per year.
Study Species Adult CM renewal p
Bergmann et al., 2009 Human 1% to less than 0.5
Kajstura et al., 1998 Human 10.5%*
Kajstura et al., 2010a Human 7%–40%
Kajstura et al., 2010b Human 7.3%–51.1%*
Mollova et al., 2013 Human 1.6% to 0.04%
Bersell et al., 2009 Mouse No renewal [20,50
analyzed
(p-H3)]
Hosoda et al., 2009 Mouse 50%–80%*
Malliaras et al., 2013 Mouse 1.3%–4.0%
Senyo et al., 2013 Mouse 0.76%
Soonpaa and Field, 1997 Mouse b1%*
Walsh et al., 2010 and personal
communication
Mouse No renewal (300,00
analyzed)heavily debated. In this review, we will provide an overview
of cardiomyocyte renewal, with a focus on human hearts,
and reveal potential pitfalls and misinterpretations. Fur-
thermore, we will elaborate how endogenous repair mech-
anisms can be exploited for future regenerative strategies.Magnitude of adult cardiomyocyte turnover
Evidence shows that the mammalian heart retains the
capability to renew cardiomyocytes during adulthood.
However, the magnitude of myocyte renewal in adult
mammals, particularly in humans, is controversial (see
Table 1 for adult mouse and human turnover rates). We
and others have independently reported that the adult
human heart has low but detectable regenerative capacity
(Bergmann et al., 2009; Mollova et al., 2013), whereas other
groups, mainly one research group, have reported that the
human heart has the regenerative capacity to renew
completely within 5 years or even more rapidly after cardiac
infarction (Kajstura et al., 1998, 2010a,b).
One argument for the markedly high turnover of
myocytes has been the detection of apoptotic and necrotic
myocytes (Anversa et al., 2013). Indeed, cell death has been
found in cardiac pathologies and in healthy myocardium
(Mallat et al., 2001; Olivetti et al., 1997; Saraste et al.,
1999). The critical parameters to establish the magnitude of
cell death are the frequency of dying cells and the duration
of an apoptotic-necrotic cell phenotype. To date, there is no
consensus on the length of the apoptotic-necrotic cell
phenotype in cardiomyocytes. Estimates range from a few
hours to days, making the extrapolation of death rates per
year or even over a lifetime problematic (De Saint-Hubert et
al., 2009; Rodriguez and Schaper, 2005; Takemura et al.,
2013). Moreover, the TUNEL technique, which detects
apoptosis by identifying DNA nicks, is not solely specific for
programmed cell death and might also label cells undergoing
DNA repair (Kanoh et al., 1999).; immunohistochemistry: IHC; NR: not reported; phospho-histone
er year (%) Renewal after injury/in
diseased hearts
Methodology
% NR 14C dating
Increased Mitotic index
NR IHC (apoptosis,
proliferation,
senescence)
NR IdU labeling (cancer
patients)
NR Mitotic index (p-H3)
1 CMs Increased Mitotic index (p-H3)
and
aurora B labeling
Increased BrdU labeling
Increased BrdU labeling
Increased 15N-thymidine labeling
Increased 3H-thymidine labeling
0 CM nuclei NR BrdU labeling
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difficult to establish. The most common tools to study
proliferation have been immunohistochemical markers of
proliferation such as Ki67 or the mitotic marker phospho-
histone 3 (p-H3). However, because only a short glimpse of
the proliferating cells can be achieved, establishing turnover
dynamics in cell populations is problematic. For example,
whether only a small subpopulation of cells renews and the
majority of cells are quiescent remains unknown. This
scenario would cause a dramatic overestimation of the
overall cell turnover. Another shortcoming of this strategy is
that cardiomyocytes derived from a stem cell population
would not be detected or the number would be under-
estimated because only cycling myocytes that already
expressed a myocyte lineage commitment would be identi-
fied. A birth marker that is incorporated into CSCs or
duplicating cardiomyocytes is required to chase newborn
myocytes and establish their number and survival in the
human heart. Thymidine analogs such as bromodeoxyuridine
(BrdU) or iododeoxyuridine (IdU), which are incorporated in
the S-phase of the cell cycle and can be detected by
antibody labeling, are powerful tools that have helped
establish the lineage of stem cell populations in various
organ systems, including the brain. In a seminal study by
Eriksson et al., brain specimens from cancer patients who
received BrdU at a diagnostic dosage were analyzed for BrdU
incorporation in adult neurons in the dentate gyrus of the
hippocampus (Eriksson et al., 1998). Importantly, these patients
had not received any cancer treatment prior to or at the time of
the BrdU infusion. Using the same strategy, Kajstura et al.
reported a high number of IdU-positive cardiomyocytes (2.5%–
46%) in cancer patients who received IdU mostly in therapeutic
dosages (approximately 10-fold higher than the diagnostic IdU
dosage) along with radiotherapy directed to different organs
(Kajstura et al., 2010b). The high frequency of IdU-positive
cardiomyocytes was similar to fibroblasts, even exceeding the
labeling frequency of endothelial cells, and (in some tumor
tissues) raises questions regarding the interpretation of the data
(Laflamme and Murry, 2011). Moreover, given the reported high
renewal rate of cardiomyocytes, the IdU label would be diluted
out within the first 5 cell divisions shortly after the last IdU pulse
(Wilson et al., 2008). Even including the possibility of label
retention in dividing cardiomyocyte and stem cells, labeling
frequencies of 24% and 46% are incompatible with extensive
chasing periods of 1472 and 660 days, respectively, until the
death of the patients (see supplement Bergmann et al., 2011).
Thus, the fraction of IdU-labeled cardiomyocytes cannot be
explained only by renewal, and other possibilities (such as
aberrant DNA synthesis)must be considered (Burns et al., 2007).
The reported 64-fold higher apoptosis rate of myocytes in the
IdU study compared with healthy controls also questions the
health status of the examined hearts, which might partly
explain the high frequency of IdU incorporation (Kajstura et al.,
2010b; Olivetti et al., 1997). Human myocytes show extensive
polyploidy during growth and in disease (as discussed below).
This process complicates the use of IdU labeling when ploidy
levels are not taken into consideration (Bergmann et al., 2011).
14C retrospective dating is a new technology to overcome
limitations in measuring cardiomyocyte renewal in human
hearts (Bergmann et al., 2009, 2012; Huttner et al., 2014;
Spalding et al., 2013). This strategy is based on the
incorporation of nuclear test bomb-derived 14C into genomicDNA; therefore, it provides a cumulative measure for
cellular turnover that is different from immunohistochemi-
cal strategies (Spalding et al., 2005).
To determine the myocardial turnover, the correct
identification of cardiomyocytes and/or cardiomyocyte nuclei
is critical and has been challenging (Ang et al., 2010). Because
most archived heart tissue is only available frozen, an
isolation strategy based on the cellular level is not feasible.
Rather, we identified three independent markers [cardiac
troponins I and T and pericentriolar protein 1 (PCM-1)] to
identify and isolate cardiomyocyte nuclei (Bergmann et al.,
2009, 2011; Bergmann and Jovinge, 2012). PCM-1, a protein
associated with the centrosome complex, accumulates
perinuclearly in a cell type-specific fashion in mature
cardiomyocyte and skeletal muscle cells (Fant et al., 2009;
Srsen et al., 2009). PCM-1 labeling identifies cardiomyocyte
nuclei for isolation in different species, including mice and
humans, in fresh and frozen post-mortem tissues (Bergmann
and Jovinge, 2012; Bergmann et al., 2011). The insoluble
perinuclear matrix remains in most phases of the cell cycle
but disassembles only in pro-metaphase and metaphase of
mitosis (Srsen et al., 2009), making it possible to visualize
myocyte nuclei almost throughout the whole cell cycle.
Applying the 14C birth dating strategy to human
cardiomyocytes in the left ventricle, we have reported a
low but detectable annual turnover rate that declines to
values below 0.5% in aged subjects (Bergmann et al., 2009).
Our measured 14C concentrations are not compatible with a
massive increase in the number of cardiomyocytes in
growing hearts, as suggested in rodents (1.4-fold) and in
young humans (3.4-fold) (Mollova et al., 2013; Naqvi et al.,
2014). The increase in cardiomyocyte count in preadolescent
rodents, however, might correspond to the increase in
ploidy in humans, as discussed below.Ploidy and Multinucleation of Cardiomyocytes
When cardiomyocytes enter the cell cycle, they do not
always progress through the entire cell cycle and generate
new daughter cells (Fig. 1). Instead, during physiological
heart growth, a large fraction (studies report from 12% to
values exceeding 50%) of human cardiomyocytes undergo
polyploidization mainly during the physiological growth of
the heart (Adler, 1991; Bergmann et al., 2009; Mollova et
al., 2013; Takamatsu et al., 1983). During adulthood, the
DNA content per nucleus remains constant in healthy hearts
throughout life (Bergmann et al., 2009). In contrast, in
murine cardiomyocytes, where only a small fraction of
cardiomyocyte nuclei become polyploid (Adler et al., 1996;
Bergmann and Jovinge, 2012), 93%–95% of all myocytes have
become binucleated by 2 weeks after birth (Soonpaa et al.,
1996; Walsh et al., 2010), and there is also a small fraction of
tri- and tetranucleated cardiomyocytes at 3 months (Rota et
al., 2007). Analysis of the gene expression patterns shows a
down-regulation of genes involved in cell cleavage and
cytokinesis at the beginning of binucleation (Walsh et al.,
2010). One might speculate that binucleation is caused
mainly by halted cytokinesis rather than fusion. Moreover,
not only physiological heart growth but also various heart
diseases, including congenital heart disease (Adler, 1976),
adverse remodeling after cardiac infarction (Herget et al.,
526 O. Bergmann, S. Jovinge1997; Meckert et al., 2005) and cardiac hypertrophy are
triggers for extensive polyploidization (Vliegen et al., 1995).
Interestingly, patients with end-stage dilated cardiomyopa-
thy treated with a left ventricular assist device (LVAD) as a
bridge for heart transplantation show a decreased ploidy
level, indicating either the selective death of larger
cardiomyocytes with high ploidy levels or the new formation
of small cardiomyocytes with diploid nuclei (Rivello et al.,
2001; Wohlschlaeger et al., 2010).
Apart from genetic fate-mapping strategies, both Ki-67
labeling and birth dating with thymidine analogs or 14C might
be confounded by polyploidization and multinucleation.
Analyses should therefore be performed at the nuclear
level. Thus, additional measures are required to establish
turnover in cardiomyocytes. In contrast, the incorporation of
thymidine analogs or 14C into mononucleated and diploid
cardiomyocytes always marks an adult-born cardiomyocyte
and cannot be attributed to cell or nuclear ploidy.
Cytokinesis with the formation of the cleavage furrow is
the last step completing cellular division. Aurora B kinase is
a chromosomal passenger protein that is localized in
different subcellular compartments during mitosis. During
cytokinesis, aurora B kinase targets required proteins of the
contractile ring at the site of cytoplasmic separation.
Detecting aurora B kinase by immunohistochemistry at the
cleavage furrow is a method for visualizing cytokinesis and
thereby demonstrating cell division (Tatsuka et al., 1998). A
stringent analysis of myocyte renewal that accounts for the
above-described confounders is crucial for establishing the
magnitude of myocyte proliferation, particularly when
studying diseased hearts. Because 14C birth dating can
account for polyploidization either by selective 14C dating
of diploid cardiomyocytes or by mathematical correction for
measured ploidy, it is also possible to investigate renewal in
heart diseases, in which the ploidy levels are higher than in
healthy hearts (Bergmann et al., 2009).CSCs as a source of adult cardiomyocytes
One decade has passed since Beltrami and co-workers
provided evidence for the existence of c-kit-expressing
cardiac stem cells (CSCs) (Beltrami et al., 2003). The
presence of cells that express c-kit, the stem cell factor
receptor, in the absence of any hematopoietic lineage
markers, may allow for the generation of all major lineages
in the heart, including cardiomyocytes, endothelial cells and
mesenchymal cells in vitro and in vivo (Beltrami et al., 2003).
Several other putative CSCs in the adult heart have been
reported since then [for a review, see (Stamm et al., 2009)].
CSCs typically express adult stem cell genes, such as c-kit,
stem-cell antigen 1 (Sca-1) (Oh et al., 2003) or multidrug
resistance protein 1 (MDR1). Other CSCs have been identified
as side population (SP) cells (Martin et al., 2004), perivascular
cells (Galvez et al., 2008) or cardiosphere-derived cells
(Smith et al., 2007). Although studies have reported their
cardiogenic potential in vitro and in various transplantation
paradigms (Passier et al., 2008), appropriate in vivo fate-
mapping strategies for most stem cell markers have been
lacking until recently. However, Islet1 (Isl1) stem cells were
described by lineage tracing during development (Moretti et
al., 2006). Isl1 cells can be isolated from the neonatal heartand then expanded and differentiated into cardiomyocyte in
vitro (Laugwitz et al., 2005). Because the number of Isl1 cells
decreases soon after birth, these cells resemble a remnant
progenitor population from development. A potential new
CSC population in the epicardial layer of the heart has been
reported. Adult lineage-tracing revealed a re-activation of
Wilms tumor 1 (Wt1)-expressing epicardial cells under
ischemic conditions, and the ligand thymosin beta-4 could
further increase their number. However, the total contribu-
tion of these cells to new myocytes is limited (Smart et al.,
2011).
The cardiomyogenic potential of c-kit-expressing cells is
likely the most studied aspect among the described CSCs.
The proliferation and survival of hematopoietic stem cells,
germ cells and other lineages is dependent on c-kit
activation by binding to its ligand the stem cell factor
(SCF). The role of residing c-kit-expressing cells in the
postnatal and adult heart is, however, much more contro-
versial. Using a BAC transgenic mouse that expresses EGFP
under transcriptional control of the kit locus, Tallini and
colleagues showed that clonally isolated and differentiated
EGFP (c-kit)-positive cells from the neonatal mouse heart
can give rise to cardiomyocytes, smooth muscle cells, and
endothelial cells (Tallini et al., 2009). Zaruba et al. obtained
a similar result when isolating c-kit-positive cells by flow
cytometry from a transgenic myocyte reporter mouse
(Zaruba et al., 2010). In response to cryo- and ischemic
injury, EGFP (c-kit) expression is not limited to undifferen-
tiated cells but is also found in three cardiac lineages,
indicating that multipotent progenitor cells express c-kit at
the neonatal stage (Jesty et al., 2012; Tallini et al., 2009). In
contrast, in adult hearts, the number of c-kit-expressing
cells decreases dramatically, and EGFP (c-kit) expression is
restricted to endothelial cells and smooth muscle cells,
suggesting that they have a role as vascular progenitor cells
(Jesty et al., 2012; Tallini et al., 2009). A recent study,
however, suggested that c-kit-positive cells in the adult
mouse heart were capable of regenerating cardiomyocytes
after diffuse myocardial damage with isoproterenol (Ellison
et al., 2013). The novel aspect in this study was direct
evidence with a fate mapping strategy that c-kit-positive
cells show in vivo stem cell potential. The authors used a
lentiviral-based Cre-Lox strategy to label and track
c-kit-expressing cells in the heart. The specificity of the
c-kit promoter expression, which is critical to their
approach, however, has been questioned (Molkentin and
Houser, 2013). Van Berlo and colleagues devised a strategy
to genetically label and track c-kit-positive cells and their
progeny in the mouse heart. They targeted the Kit locus
using a Cre recombinase (Kit-Cre) and a tamoxifen-inducible
MerCreMer chimeric protein (Kit-MCM), and they bred these
mice with a reporter line (Rosa26-eGFP) to permanently
label the lineage (van Berlo et al., 2014). Using the Kit-Cre
mouse with a constitutively active Cre from the zygote
stage, the authors found that c-kit-positive cells contributed
to 0.027% of the cardiomyocyte lineage 4 weeks postnatally
(80% recombination rate of c-kit-positive cells in the heart),
which is much lower than that suggested from previous
studies (Hosoda et al., 2009; Kajstura et al., 2010a). Even
4 weeks after cardiac infarction or treatment with isopro-
terenol, the c-kit-positive cell contribution to the myocyte
lineage in the tamoxifen-inducible Kit-MCM mouse was only
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tered continuously over the whole time period starting two
weeks and three weeks prior to injury or only before the
ischemic injury with a similar outcome. However, there was a
large c-kit lineage contribution to the endothelium that
increased after cardiac infarction, in agreement with earlier
studies (Sandstedt et al., 2010). The authors further showed
that approximately 80% of all recombined EGFP-positive
cardiomyocytes resulted from cell fusion. Because tamoxifen
was given in one experimental approach strictly before the
injury, the possibility of labeling pre-existing cardiomyocytes
that then upregulated c-kit expression after injury seems to
be unlikely.
Uchida and co-workers performed another fate mapping
study based on the tet-cre system to chase sca-1–expressing
cells and their descendants in the murine heart (Uchida et
al., 2013). The authors showed that sca-1 expression is
restricted to the non-myocyte compartment and demon-
strated that sca-1-derived cells contribute to a small
percentage of all cardiomyocytes at a constant rate during
normal aging. Pressure overload, but not ischemic damage,
caused a modest increase in the contribution to the
pre-existing cardiomyocyte cell pool. The restriction of a
subpopulation might have underestimated the extent of
cardiomyogenesis, and it is not clear whether sca-1-positive
cells divide before differentiation into cardiomyocytes.
Because only a minority of sca-1-positive cells in the murine
heart resemble CSCs and sca-1 does not exist in humans,
further studies are necessary to unveil the exact nature and
marker profile of sca-1-positive CSCs. Of note, a subpopu-
lation of sca-1-positive cells, which were negative for the
hematopoietic marker CD45 and the endothelial marker
CD31, co-expressed the putative CSC marker c-kit (1.6%)
(Uchida et al., 2013).
Clinical trials using expanded autologous CSCs
(c-kit-positive and cardiosphere-derived cells) have been
initiated (Bolli et al., 2011; Malliaras et al., 2013). Patients
with post-infarction left ventricular dysfunction received
autologous CSCs through their coronary arteries. Preliminary
data suggest improved clinical parameters and reduced scar
size. However, given the latest lineage tracing studies
showing little in vivo contribution of c-kit-positive cells to
the cardiomyocyte lineage, the mode of action of the
delivered cardiac cells remains unclear. Paracrine effects
on myocyte survival and angiogenesis and a direct contribu-
tion to the endothelial lineage should be considered, similar
to what has been proposed, as a mode of action in the bone
marrow mononuclear cell infusion trials (Yoon et al., 2010).
Mature cardiomyocytes as a source for the
adult generation of cardiomyocytes
Apart from CSC-derived cardiomyocytes, self-duplication of
pre-existing cardiomyocytes has been reported. Adult
zebrafish regenerate myocardium after amputation of the
apical portion of the heart (Poss et al., 2002). Using a
tamoxifen-induced Cre-Lox system under the control of the
mature cardiomyocyte-specific cmlc2-promoter, pre-existing
cardiomyocytes can be labeled before amputation and chased
thereafter. The proportion of labeled cardiomyocytes
(EGFP-positive) was unchanged in the regeneratedmyocardium, indicating that the source was mature
cardiomyocytes (Kikuchi et al., 2010). Similarly, a generalized
injury (depletion of 60% of the cardiomyocytes in the heart by
a suicide gene approach) created a heart failure phenotype,
which completely recovered by replication of pre-existing
cardiomyocytes within 30 days (Wang et al., 2011). The latter
finding would indicate a widespread regenerative capacity
within the myocardium of zebrafish. The regenerative
capacity of another species, the newt, which has a general
high regenerative competence within its adult individuals,
has been studied at the single-cell level. Culturing isolated
cardiomyocytes revealed that only 1/3 of the cardiomyocytes
enter the cell cycle and mitosis, suggesting that even in a
highly regenerative species, such as the newt, the myocardi-
um is heterogeneous (Bettencourt-Dias et al., 2003).
Similar to what has been shown in lower vertebrates, the
neonatal mouse heart can regenerate myocardium to a
substantial extent. Under physiological conditions, cardio-
myocyte proliferation decreases to adult levels within the
first two weeks, while mouse myocyte become binucleated
(Soonpaa et al., 1996; Walsh et al., 2010). Porrello and
colleagues showed that an apical amputation of the
myocardium at postnatal day one could result in complete
regrowth without scar formation within 21 days, although
the degree of regeneration has been questioned (Andersen
et al., 2014). Regrowth is restricted to the first postnatal
days; by postnatal day 7, the hearts fail to regenerate the
apex. This process was investigated using an inducible
recombination technique similar to that performed in
zebrafish using the inducible expression of LacZ in cardio-
myocyte (myosin heavy chain isoform alpha expressing cells)
(Porrello et al., 2011). Even if the recombination by
induction was incomplete (only approximately 60% of the
cardiomyocytes was LacZ-positive), the proportion was
constant in the apex after injury, suggesting that the source
of regenerating cardiomyocyte after injury was mainly
pre-existing cardiomyocytes. A similar regenerative re-
sponse was seen in response to ischemic injury performed
at postnatal day 2 (Porrello et al., 2013).
The cell cycle arrest seen postnatally might be explained
by an increase in oxygenation compared with the fetal state
(Puente et al., 2014). Puente et al. showed that the level of
reactive oxygen species (ROS) increases postnatally along
with oxidative DNA damage and the DNA damage response
(DDR), whereas a reduction of oxygen levels and an
inhibition of the DDR response extends the proliferative
window in the postnatal heart.
Importantly, mechanisms that govern cardiomyocyte
renewal during the neonatal period might be applied to
unravel adult myocardial regeneration. For instance, the
micro-RNA 15 family and Yes-associated protein (Yap), a
transcriptional co-factor in the Hippo signaling pathway,
modulate cardiomyocyte renewal not only in neonatal
cardiomyocytes but also in adult mouse hearts (Porrello et
al., 2013; Xin et al., 2013). Moreover, the homeodomain
transcription factor Meis1 regulates cardiomyocyte cell
cycle arrest (Mahmoud et al., 2013).
The previously mentioned transgenic model for chasing
pre-existing myocytes (EGFP-positive) was also used in adult
mice to determine the source of newly born myocytes. The
infarcted myocardium was partly replaced with untagged
cardiomyocytes (EGFP-negative), suggesting that the new
528 O. Bergmann, S. Jovingecardiomyocytes were derived from a more immature source
(Hsieh et al., 2007; Loffredo et al., 2011). However, the
same research group reported contradictory findings within
the same model in studies that were extended with
multi-isotope imaging mass spectrometry (MIMS). MIMS
allows for the detection of multiple isotopes on ultrathin
sections. This technique made it possible to administer 15N
thymidine for several months to mice without getting the
toxic effects of the commonly used thymidine analog BrdU.
In this study, almost all 15N thymidine-incorporating cells
were EGFP-positive indicating that pre-existing myocyte
self-replicated and generated new myocytes after injury and
at a low degree in homeostasis (Senyo et al., 2013). The
reason for the reported decrease in EGFP-positive myocytes
is not completely understood. Either the recombined
myocytes might be more prone to undergo apoptosis or
CSCs directly differentiate into cardiomyocytes without
progressing through the cell cycle, which would exhaust
the CSC pool.
If cardiomyocytes are the source of adult regeneration,
then the mechanism for cell cycle re-entry is unknown.
Would these cells really exhibit an adult phenotype, which
includes an extensive contractile apparatus and a cytoplasm
filled with mitochondria? Dedifferentiation of myocytes with
the disassembly of the cells' sarcomeric structure, detach-
ment from one another and the expression of cell-cycle
regulators has been described in zebrafish (Kikuchi et al.,
2010). Disassembled sarcomeres in regions with high prolif-
erative activity have also been reported in injured neonatal
hearts (Porrello et al., 2013). Architectural changes in
myocytes seem to be required to re-enter the cell cycle
and undergo cytokinesis. In injured adult myocardium, the
so-called remodeling is connected to the re-expression of
genes from fetal and embryonic stages along with myocyte
dedifferentiation. These processes may be important to
cope with hypoxia and overload-related cell death [for
review (Szibor et al., 2013)]. However, why the adult
dedifferentiated cardiomyocyte does not undergo cytokine-
sis to the same magnitude as the neonatal heart is not
understood. Molecular profiling strategies comparing the
two similar but different age-related stages of myocyte
dedifferentiation might provide a more comprehensive
understanding of the mechanisms of cycling myocytes.Future hopes and directions
Efficient myocardial regeneration in humans is the ultimate
goal in cardioregenerative medicine. Lower vertebrates,
such as zebrafish with their capability to substantially renew
the adult myocardium, are important model organisms for
the basic understanding of cardiac regeneration. The
exciting question why higher vertebrates lose most of their
ability to regenerate their hearts after an injury might help
us to devise new strategies to trigger the existing regener-
ative capacity in adult hearts.
Thus, the endogenous generation of cardiomyocytes
holds promise because generated bona fide cardiomyocytes
appear to be well-integrated and (at least in regenerative,
lower vertebrate models) have been demonstrated to
significantly, not only statistically but also biologically,
improve cardiac function after injury.Additionally, it would be highly desirable tomanipulate CSCs
to improve their survival and direct them efficiently to the
myocyte lineage. A recently developed technology to deliver
mRNA in vivo shows promise. Modified RNA (modRNA) encoding
human vascular endothelial growth factor-A (VEGF-A) improves
heart function and enhances the long-term survival of the
murine recipients. These improvements were at least partly
mediated by an expansion of epicardial Wt1-positive CSCs
and their promotion toward the endothelial and cardiomyo-
cyte lineage (Zangi et al., 2013).
Most studies on adult heart regeneration have been
conducted in rodents with hearts that are several hundred-
fold smaller than the human equivalents. Furthermore, the
expression profile of CSCs might be different in rodents
compared with humans. Sca1, for example, is not conserved
throughout species and does not exist in humans.
The .therapeutic efficiency of CSCs, stem cell-derived
cardiomyocytes or small molecules delivered to the myocar-
dium can only be assessed in a clinical-relevant model of
cardiac disease. Animal models that better resemble the
human situation are therefore greatly needed to translate the
knowledge we have obtained in lower vertebrates and rodents
to the clinic. Accordingly, in a recent study conducted in
non-human primates, Chong and colleagues showed that a
graft of human embryonic stem cell-derived cardiomyocytes
remuscularized the infarcted macaque heart and electrically
coupled to the host myocardium (Chong et al., 2014).
Today, site-specific nucleases such as TALEN and CRISPR/
Cas make it possible to introduce custom modifications into
genomic DNA (genome editing) [for review see (Gaj et al.,
2013)]. This technology allows, for the first time, the
generation of transgenic animals without having to establish
stable ES cell lines. Recently, a Cre-inducible EGFP reporter
pig line was generated using TALEN-mediated genomic
editing of the ROSA26 locus (Li et al., 2014). Swine has
traditionally served as a model animal for cardiac surgeons
because their heart physiology closely resembles the
human. Therefore, genome editing technology has the
potential to facilitate translational studies to delineate the
regulation of myocardial regeneration and thereby facili-
tate the stimulation of “regenerative” pathways to treat
cardiac diseases.References
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